Clotting factor concentrates

/Clotting factor concentrates
Clotting factor concentrates2018-09-05T17:58:19+00:00

Charts

Recombinant factor VIII chart


Interviews

Rebinyn, an extended half-life factor IX

Rebinyn, an extended half-life factor IX concentrate, manufactured by Novo Nordisk, is one of the “winners” in the recent Canadian Blood Services tender for the 2018-2020 period.

For its March 2018 issue, Hemophilia Today interviewed Dr. Manuel Carcao, pediatric hematologist and co-director of the Comprehensive Care Hemophilia Program at The Hospital for Sick Children in Toronto and lead author of the Paradigm 5 study on the use of Rebinyn in children, and Dr. Hossam Saad, Associate Director of Biopharm Medical Affairs at Novo Nordisk Canada, to learn more about this new therapy.

CLICK HERE to read the interview.

 

NUWIQ, another recombinant factor VIII option

With the approval of Nuwiq by Health Canada and its success in obtaining a share of the factor VIII market in provinces served by Canadian Blood Services, Hemophilia Today sat down with Lidia Cosentino, Ph.D., director of medical and scientific affairs at Octapharma Canada, and Dr. Anthony K. C. Chan, pediatrician and co-director of the hemophilia program at Hamilton Health Sciences Centre, to learn more about this coagulation therapy.

CLICK HERE for the full interview.

 
Bayer introduces KOVALTRY to replace Kogenate FS in Canada

Bayer introduces Kovaltry to replace Kogenate FS in Canada Kogenate and Kogenate FS have been used in Canada to treat hemophilia A for almost a quarter-century. Their manufacturer, Bayer, is now replacing Kogenate FS with Kovaltry in the Canadian marketplace.

Hemophilia Today met with Mohammed Mahdi, medical and scientific advisor in the Hematology Branch at Bayer Canada, and Jayson Stoffman, medical director at the Manitoba Bleeding Disorders Program and past-president of the Association of Hemophilia Clinic Directors of Canada, to learn more about Kovaltry.

CLICK HERE to read the interview.


ELOCTATE, a longer half-life factor VIII, approved by Health Canada

Eloctate™, a recombinant factor VIII concentrate manufactured by Biogen, was approved by Health Canada on August 26, 2014. It is indicated in adults and children with hemophilia A for routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes and for control of bleeding episodes.

Hemophilia Today (HT) interviewed two physicians who were closely involved with the development and clinical trials of Eloctate.

CLICK HERE to read the interview.


ALPROLIX, a longer half-life factor IX, approved by Health Canada

Alprolix™, a recombinant factor IX concentrate manufactured by Biogen Idec, was approved by Health Canada March 21, 2014 and by the U.S. FDA a week later. It is indicated in adults and children with hemophilia B for routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes and for control of bleeding episodes.

Hemophilia Today (HT) interviewed two physicians who were closely involved with the development and clinical trials of Alprolix.

CLICK HERE for the full interview.

Do NOT follow this link or you will be banned from the site!